Trinity Biotech (TRIB) Net Income towards Common Stockholders (2009 - 2024)
Trinity Biotech (TRIB) posted quarterly Net Income towards Common Stockholders of -$17.0 million for Q4 2024, down 208.16% year-on-year from $15.7 million in Q1 2024, and down 256.27% on a QoQ basis from -$4.8 million in Q3 2024.
Trinity Biotech (TRIB) Net Income towards Common Stockholders (2009 - 2024) Analysis & Trends
Trinity Biotech (TRIB) has reported Net Income towards Common Stockholders for 16 consecutive years, with -$17.0 million the latest figure, recorded in Q4 2024.
- Quarterly Net Income towards Common Stockholders fell 208.16% year-over-year to -$17.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2025 was -$21.7 million (up 31.69% YoY) and the FY2025 annual result came in at -$37.4 million, down 17.61% from the prior year.
- Net Income towards Common Stockholders declined to -$17.0 million in Q4 2024 per TRIB's latest filing, from -$4.8 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for TRIB reached as high as $7.3 million in Q3 2020 and fell as low as -$17.0 million in Q4 2024.
- A 5-year average of -$5.1 million and a median of -$5.7 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The largest YoY upside for Net Income towards Common Stockholders was 29200.0% in 2020 against a maximum downside of 1152183808.05% in 2020.
- Year by year, Net Income towards Common Stockholders stood at -$10.0 million in 2020, then surged by 87.39% to -$1.3 million in 2021, then slumped by 697.47% to -$10.1 million in 2022, then jumped by 45.42% to -$5.5 million in 2023, then slumped by 208.16% to -$17.0 million in 2024.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$17.0 million, -$4.8 million, and -$6.8 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.58 Bn | 176.28 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 129.01 Bn | 126.13 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 108.52 Bn | 99.30 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 68.67 Bn | 67.22 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.33 Bn | 44.66 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.34 Bn | 27.23 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 28.07 Bn | 25.79 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - | - |
| 9 | Koninklijke Philips | 24.12 Bn | 21.00 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Trinity Biotech | 107.10 Mn | 101.96 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -16.96 Mn |
| Sep 30, 2024 | -4.76 Mn |
| Jun 30, 2024 | -6.76 Mn |
| Mar 31, 2024 | -3.32 Mn |
| Dec 31, 2023 | -5.50 Mn |
| Sep 30, 2023 | -6.72 Mn |
| Jun 30, 2023 | -5.99 Mn |
| Mar 31, 2023 | -5.81 Mn |
| Dec 31, 2022 | -10.08 Mn |
| Sep 30, 2022 | -8.95 Mn |
| Jun 30, 2022 | -9.71 Mn |
| Mar 31, 2022 | -12.28 Mn |
| Dec 31, 2021 | -1.26 Mn |
| Sep 30, 2021 | 1.32 Mn |
| Jun 30, 2021 | -783,000.00 |
| Mar 31, 2021 | 1.60 Mn |
| Dec 31, 2020 | -10.02 Mn |
| Sep 30, 2020 | 7.33 Mn |
| Jun 30, 2020 | -1.47 Mn |
| Mar 31, 2020 | -2.22 Mn |